Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Abstract

A random-sequence peptide microarray can interrogate serum antibodies in a broad, unbiased fashion to generate disease-specific immunosignatures. This approach has been applied to cancer detection, diagnosis of infections, and interrogation of vaccine response. We hypothesized that there is an immunosignature specific to ME/CFS and that this could aid in the diagnosis. We studied two subject groups meeting the Canadian Consensus Definition of ME/CFS. ME/CFS ( n = 25) and matched control ( n = 25) sera were obtained from a Canadian study. ME/CFS ( n = 25) sera were obtained from phase 1/2 Norwegian trials (NCT01156909). Sera from six healthy controls from the USA were included in the analysis. Canadian cases and controls were tested for a disease immunosignature. By combining results from unsupervised and supervised analyses, a candidate immunosignature with 654 peptides was able to differentiate ME/CFS from controls. The immunosignature was tested and further refined using the Norwegian and USA samples. This resulted in a 256-peptide immunosignature with the ability to separate ME/CFS cases from controls in the international data sets. We were able to identify a 256-peptide signature that separates ME/CFS samples from healthy controls, suggesting that the hit-and-run hypothesis of immune dysfunction merits further investigation. By extending testing of both our signature and one previously reported in the literature to larger cohorts, and further interrogating the specific peptides we and others have identified, we may deepen our understanding of the origins of ME/CFS and work towards a clinically meaningful diagnostic biomarker. Electronic supplementary material The online version of this article (10.1007/s12035-018-1354-8) contains supplementary material, which is available to authorized users.

The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)

“…Currently, there is no diagnostic test or validated biomarker for ME/CFS available (2,80), although some results give hope for a future diagnostic biomarker or the use of an immunosignature assay (13,(81)(82)(83)(84)(85) (20).…”

The Efficacy and Safety of Myelophil, an Ethanol Extract Mixture of Astragali Radix and Salviae Radix, for Chronic Fatigue Syndrome: A Randomized Clinical Trial

“…To date, two phase 3 clinical trials have been performed for CFS using the following medications: 1) a monoclonal anti-CD20 antibody, Rituximab, and 2) the nucleic acid compounds, Rintatolimod. Both of these therapies, however, did not provide more credible evidence of efficacy than the placebo (Strayer et al, 2012; Smith et al, 2014; Günther et al, 2019). These disappointing results demand the additional trials for the development of an effective therapy for CFS.…”

The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection

“…CFS patients also had a significantly higher level of IL-8 and a lower level of IL-23. Several investigators hypothesized an immune signature could be detected by antibody profiling in ME/CFS patients [ 63 , 64 ]. Few studies showed that in most cases with ME/CFS, especially in the early stages of the disease, T cells and cytokines levels are higher than the control group [ 61 , 65 ], which could be the hallmark of CFS.…”